| Literature DB >> 31640173 |
Dongxu Xing1, Guanwang Shen2, Qingrong Li3, Yang Xiao4, Qiong Yang5, Qingyou Xia6.
Abstract
Bombyx batryticatus is a well-known animal in traditional Chinese medicine. The aim of the research was to reveal the quality formation mechanism of B. batryticatus and to screen out the characteristic component used for the quality control. The anticonvulsant effects of B. batryticatus with a stiff time of one, five, and nine days (D1, D5 and D9, respectively) and healthy silkworm of the same developmental stage (SW) were determined by animal experiment. The dynamic changes in chemical composition were analyzed using UPLC-Q-TOF-MS-based metabolomics. D5 and D9 B. batryticatus exhibited significant anticonvulsant effects (p < 0.05 and p < 0.01, respectively). Accordingly, principal component analysis (PCA) and partial least squares discrimination analysis (PLS-DA) indicated that the chemical composition of D5 and D9 B. batryticatus changed significantly. The different metabolites mainly consisted of primary metabolites such as lipids and amino acids and secondary metabolites such as flavonoids, beauvericin, and glycolipids. Interestingly, the relative abundance of quercetin-7-O-β-d-4-O-methylglucoside, the characteristic component of B. batryticatus, increased with stiff time and was promised to be used as an index component of quality control. The results expand our understanding of the quality formation mechanism of B. batryticatus. In addition, it highlights the potential of UPLC-Q-TOF-MS-based metabolomics for the quality control purpose of TCMs.Entities:
Keywords: Bombyx batryticatus; UPLC-Q/TOF-MS-based metabolomics; anticonvulsant effects; quality formation mechanism; stiff time
Mesh:
Substances:
Year: 2019 PMID: 31640173 PMCID: PMC6832393 DOI: 10.3390/molecules24203780
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Formation process of B. batryticatus. (a) Beauveria bassiana spores; (b) silkworm larva; (c) death of silkworm infected by Beauveria bassiana; (d) B. batryticatus.
Figure 2Changes in B. batryticatus during the stiff stage. (A) Appearance changes. D1, D3, D5 and D9 indicate 1, 3, 5 and 9 days after B. batryticatus death; (B) mass changes. The statistical data were treated by ANOVA and Student-Newman-Keuls (S-N-K) test. Different letters refer to the significant differences (p < 0.05).
Efficacy of B. batryticatus samples on strychnine-induced epileptic seizures in mice.
| Groups | Clonic Seizure Latency/s | Tonic Seizure Latency/s | Mortality Protection Rate/% |
|---|---|---|---|
| Control | ns | ns | 100 |
| Model | 163.00 ± 12.60 | 223.90 ± 26.57 | 10 |
| SW | 177.4 ± 19.29 | 356.6 ± 160.63 | 20 |
| D1 | 187.70 ± 19.78 | 387.10 ± 157.66 | 20 |
| D5 | 222.10 ± 16.93 * | 435.80 ± 152.97 | 30 |
| D9 | 280.30 ± 21.86 ** | 684.60 ± 188.78 * | 40 |
ANOVA and least significant difference (LSD) tests are used to compare the clonic seizure latency and tonic seizure latency, and Chi-square test is used to compare the mortality protection rate between groups. * p < 0.05 and ** p < 0.01 as compared to the model group. (p < 0.01).
Figure 3Scores plot of the principal component analysis (PCA) and partial least squares discrimination analysis (PLS-DA) of B. batryticatus from different stiff time. (a) PCA score plot (PC1 vs. PC2); (b) PCA score plot (PC1 vs. PC3); (c) PLS-DA score plot (PC1 vs. PC2); (d) PLS-DA score plot (PC1 vs. PC3); (e) presentation of chance permutation at 200 times used for the discrimination between the four groups [R2 = (0.0, 0.505), Q2 = (0.0, −0.314)].
Differential metabolites between groups (healthy silkworm samples (SW) vs. different stiff time sample D1).
| Classification | Metabolites | VIP Value | FC(SW/D1) | |
|---|---|---|---|---|
| Flavonoids | Unknown flavonoid | 1.93 | 3.51 × 10−3 | −6.06 |
| Rutin | 1.13 | 6.01 × 10−3 | −5.86 | |
| Unknown flavonoid | 1.8 | 1.63 × 10−2 | −4.51 | |
| Quercetin | 1.68 | 4.04 × 10−2 | −1.08 | |
| Kaempferol | 1.79 | 3.58 × 10−2 | 0.92 | |
| Amino acid | L-glutamine | 4.71 | 1.01 × 10−4 | −2.62 |
| L-asparagine | 1.18 | 3.10 × 10−3 | −2.37 | |
| L-arginine | 2.1 | 5.87 × 10−3 | −2.14 | |
| L-tryptophan | 1.95 | 4.20 × 10−3 | −1.02 | |
| L-histidine | 3.12 | 3.17 × 10−6 | −0.72 | |
| L-proline | 4.45 | 5.95 × 10−3 | −0.58 | |
| Lipids | TG (56:8) | 8.76 | 1.66 × 10−3 | −1.94 |
| TG (52:5) | 6.83 | 1.21 × 10−2 | −1.28 | |
| TG (54:6) | 7.25 | 6.51 × 10−3 | −1.24 | |
| TG (54:8) | 5.23 | 3.54 × 10−2 | −1.17 | |
| TG (56:7) | 9.91 | 1.89 × 10−2 | −1.11 | |
| TG (52:4) | 7.99 | 2.10 × 10−3 | −0.98 | |
| PC (36:2) | 0.73 | 1.38 × 10−3 | −0.96 | |
| Nucleosides | Adenine | 3.25 | 3.06 × 10−2 | −1.05 |
| dTDP | 1.37 | 8.34 × 10−4 | −0.94 | |
| Uracil | 2.45 | 1.64 × 10−4 | 1.26 | |
| Hypoxanthine | 6.23 | 1.11 × 10−2 | 2.09 | |
| Others | Benzoic acid | 1.56 | 2.88 × 10−2 | −1.39 |
| 2-Hydroxycinnamic acid | 1.73 | 3.08 × 10−2 | −1.37 | |
| 2-pyrrolidone-5-carboxylic acid | 5.79 | 2.84 × 10−4 | −1.02 | |
| Betaine | 4.53 | 3.37 × 10−3 | 0.65 | |
| Acetylcarnitine | 1.76 | 4.71 × 10−3 | 0.66 |
Differential metabolites between groups (D1 vs. D5).
| Classification | Metabolites | VIP Value | FC(D1/D5) | |
|---|---|---|---|---|
| Flavonoids | Kaempferol | 1.34 | 5.31 × 10−3 | −1.82 |
| Unknown flavonoid | 1.12 | 4.26 × 10−2 | −1.25 | |
| Unknown flavonoid | 1.07 | 3.08 × 10−4 | 4.41 | |
| Kaempferol-7- | 1.39 | 8.75 × 10−5 | 6.75 | |
| Quercetin-7- | 1.67 | 1.22 × 10−6 | 6.82 | |
| Amino acid | L-histidine | 1.81 | 3.67 × 10−8 | −1.8 |
| L-phenylalanine | 3.04 | 2.59 × 10−3 | 0.57 | |
| L-isoleucine | 1.5 | 2.61 × 10−2 | 0.82 | |
| L-valine | 1.79 | 1.51 × 10−5 | 0.84 | |
| L-tryptophan | 1.39 | 6.71 × 10−6 | 1.27 | |
| L-proline | 5.38 | 1.03 × 10−6 | 3.22 | |
| Lipids | DG (34:3) | 3.2 | 3.81 × 10−4 | −2.51 |
| DG (36:6) | 5.96 | 9.74 × 10−4 | −2.27 | |
| DG (36:4) | 5.67 | 5.92 × 10−4 | −1.82 | |
| DG (34:1) | 2.69 | 4.10 × 10−4 | −1.58 | |
| DG (36:5) | 2.49 | 3.61 × 10−3 | −1.34 | |
| DG (36:3) | 2.22 | 1.72 × 10−3 | −1.1 | |
| DG (36:2) | 2.85 | 1.65 × 10−3 | −1.01 | |
| DG (33:4) | 1.96 | 6.75 × 10−3 | 1.91 | |
| DG (35:5) | 2.3 | 8.92 × 10−6 | 3.37 | |
| DG (35:6) | 1.94 | 4.41 × 10−6 | 3.43 | |
| MG (18:2) | 1.67 | 3.00 × 10−2 | −0.95 | |
| Eicosatrienoic acid (C20:3) | 1.93 | 1.71 × 10−3 | −0.93 | |
| Octadecapentaenoic acid (C18:5) | 4.89 | 3.03 × 10−2 | −3.26 | |
| Octadecatrienoic acid (C18:3) | 5.32 | 9.96 × 10−4 | −0.68 | |
| Octadecenoic acid (C18:1) | 2.98 | 4.21 × 10−2 | −0.62 | |
| Stearic acid (C18:0) | 1.96 | 3.51 × 10−3 | −2.28 | |
| Octadecatetraenoic acid (C18:4) | 3.43 | 1.31 × 10−6 | 3.9 | |
| Octadecadienoic acid (C18:2) | 1.85 | 1.10 × 10−4 | 4.33 | |
| (4 | 1.63 | 1.93 × 10−4 | −1.53 | |
| (4 | 1.46 | 3.05 × 10−3 | −1.07 | |
| Phytosphingosine | 3.76 | 3.41 × 10−5 | 4.64 | |
| Nucleosides | Hypoxanthine | 3.59 | 7.35 × 10−3 | −2.48 |
| Adenine | 3.41 | 2.57 × 10−3 | 2.05 | |
| Others | 2-pyrrolidone-5-carboxylic acid | 2.27 | 3.23 × 10−4 | −1.09 |
| Choline | 3.76 | 2.54 × 10−3 | −0.91 | |
| Acetylcarnitine | 1.79 | 1.80 × 10−5 | 1.03 | |
| Betaine | 6.16 | 1.79 × 10−7 | 1.48 | |
| Benzoic acid | 1.23 | 9.91 × 10−4 | 1.83 | |
| L-carnitine | 1.97 | 6.95 × 10−9 | 1.84 | |
| 2-Hydroxycinnamic acid | 1.43 | 1.10 × 10−3 | 1.9 | |
| 6-Hydroxynicotinic acid | 1.36 | 4.38 × 10−5 | 2.86 | |
| Beauverin | 10.84 | 2.04 × 10−5 | 9.36 |
Differential metabolites between groups (D5 vs. D9).
| Classification | Metabolites | VIP Value | FC(D5/D9) | |
|---|---|---|---|---|
| Flavonoids | Unknown flavonoid | 1.2 | 3.05 × 10−2 | 1.39 |
| Quercetin-7- | 1.85 | 1.38 × 10−2 | 1.4 | |
| Kaempferol--7- | 1.64 | 1.68 × 10−2 | 1.47 | |
| Unknown flavonoid | 0.25 | 9.55 × 10−4 | 1.51 | |
| Amino acid | L-leucine | 2.49 | 7.59 × 10−5 | −3.75 |
| L-isoleucine | 2.66 | 1.64 × 10−5 | −3.43 | |
| L-phenylalanine | 5.61 | 1.11 × 10−7 | −2.94 | |
| L-tryptophan | 1.64 | 1.95 × 10−8 | −2.01 | |
| L-histidine | 0.62 | 3.54 × 10−3 | −0.64 | |
| L-valine | 1.56 | 6.66 × 10−4 | 0.44 | |
| Lipid | TG (54:8) | 1.68 | 1.35 × 10−2 | −3.46 |
| TG (52:6) | 3.62 | 4.51 × 10−3 | −3.73 | |
| TG (52:4) | 3.15 | 2.75 × 10−3 | −3.64 | |
| TG (56:7) | 3.56 | 3.18 × 10−3 | −3.43 | |
| TG (52:5) | 1.89 | 5.91 × 10−3 | −3.22 | |
| TG (54:6) | 2.03 | 4.74 × 10−3 | −2.75 | |
| TG (56:8) | 1.64 | 5.63 × 10−3 | −2.53 | |
| DG (35:5) | 1.8 | 9.32 × 10−4 | −1.35 | |
| DG (35:6) | 1.17 | 7.87 × 10−3 | −0.79 | |
| DG (33:4) | 1.5 | 5.56 × 10−3 | −0.76 | |
| DG (36:6) | 2.91 | 6.60 × 10−3 | 0.99 | |
| DG (36:2) | 3.95 | 2.45 × 10−5 | 1.4 | |
| DG (34:1) | 2.6 | 1.87 × 10−5 | 1.42 | |
| DG (34:3) | 2.96 | 3.16 × 10−6 | 2.17 | |
| DG (36:4) | 7.5 | 2.69 × 10−7 | 2.24 | |
| DG (36:3) | 4.48 | 1.01 × 10−6 | 2.25 | |
| DG (36:5) | 4.48 | 2.10 × 10−5 | 2.32 | |
| MG (22:6) | 1.79 | 1.60 × 10−2 | 0.44 | |
| MG (18:1) | 3.84 | 1.54 × 10−2 | 1.82 | |
| MG (20:3) | 1.95 | 8.64 × 10−5 | 1.89 | |
| MG (18:2) | 6 | 3.01 × 10−5 | 3.17 | |
| Octadecadienoic acid (C18:2) | 1.84 | 1.45 × 10−4 | −3.63 | |
| Octadecatetraenoic acid (C18:4) | 3.3 | 4.34 × 10−6 | −2.71 | |
| Eicosatetraenoic acid (C20:4) | 1.4 | 3.33 × 10−2 | −0.2 | |
| LPC (14:1) | 1.46 | 2.92 × 10−3 | 3.19 | |
| LPC (18:1) | 2.53 | 2.84 × 10−6 | 3.2 | |
| LPC (18:2) | 3.2 | 7.82 × 10−9 | 5.17 | |
| PC (36:2) | 3.07 | 2.06 × 10−6 | 6.2 | |
| PC (36:4) | 4.35 | 3.20 × 10−7 | 6.69 | |
| PC (36:5) | 3.98 | 1.85 × 10−5 | 7.04 | |
| (4 | 1.23 | 7.35 × 10−5 | −1.48 | |
| Phytosphingosine | 2.75 | 2.02 × 10−3 | −1.22 | |
| Nucleosides | Sphinganine | 1.36 | 1.23 × 10−2 | −1.12 |
| Xanthine | 2.45 | 2.83 × 10−3 | −4.5 | |
| Hypoxanthine | 1.43 | 2.58 × 10−2 | −2.38 | |
| Adenine | 3.32 | 3.28 × 10−3 | −1.76 | |
| Acetylcarnitine | 2.48 | 4.63 × 10−9 | −3.23 | |
| Others | 2-Hydroxycinnamic acid | 1.51 | 1.97 × 10−4 | −1.95 |
| Benzoic acid | 1.32 | 8.65 × 10−5 | −1.96 | |
| 2-pyrrolidone-5-carboxylic acid | 1.7 | 9.20 × 10−6 | −1.19 | |
| Betaine | 7.79 | 2.43 × 10−8 | 0.99 | |
| L-carnitine | 2.4 | 3.99 × 10−8 | 1.03 | |
| 6-Hydroxynicotinic acid | 2.1 | 5.97 × 10−3 | 1.78 |
Figure 4Changes in chemical constituents of B. batryticatus during the stiff stage.
Figure 5Relative abundance of eight chemical constituents. (A) L-Histidine; (B) choline; (C) 2-pyrrolidone-5-carboxylic acid; (D) L-carnitine; (E) betaine; (F) 6-hydroxynicotinic acid; (G) quercetin-7-O-β-d-4-O-methylglucoside; (H) kaempferol-7-O-β-d-4-O-methylglucoside.